share_log
Breakings ·  Sep 30 14:05
Modalis Therapeutics: FDA Grants Rare Pediatric Disease Designation to Mdl-101 for the Treatment of Congenital Muscular Dystrophy Type 1a (Lama2-Cmd)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment